Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical trial NCT00865969 · COMPLETED

Trial details

NCT number: NCT00865969
Sponsor: Spectrum Pharmaceuticals, Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma

Start date: 2008-12-15
Primary completion: 2013-11-05
Enrollment: 129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.